|本期目录/Table of Contents|

[1]常彬霞,田辉,薛兰,等.酒精性肝病的药物治疗靶点[J].传染病信息,2018,02:108-111.
 CHANG Bin-xia,TIAN Hui,XUE Lan*,et al.Drug therapeutic targets of alcoholic liver disease[J].Infectious Disease Information,2018,02:108-111.
点击复制

酒精性肝病的药物治疗靶点(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2018年02期
页码:
108-111
栏目:
导向与述评
出版日期:
2018-03-20

文章信息/Info

Title:
Drug therapeutic targets of alcoholic liver disease
作者:
常彬霞田辉薛兰邹正升
100039 北京,解放军第三〇二医院非感染性肝 病诊疗与研究中心(常彬霞、田辉、邹正升);100036 北京, 原总后机关第一门诊部医务室(薛兰) 前两位作者对本文有同等贡献,均为第一作者
Author(s):
CHANG Bin-xia TIAN Hui XUE Lan* ZOU Zheng-sheng*
Diagnosis and Treatment Center of Non-infectious Liver Disease, 302 Military Hospital of China, Beijing 100039, China CHANG Bin-xia and TIAN Hui are the first authors who contributed equally to the article
关键词:
酒精肝脏炎症激素白介素-22
Keywords:
alcohol liver inflammation hormone interleukin-22
分类号:
R575;R453
DOI:
10.3969/j.issn.1007-8134.2018.02.004
文献标识码:
A
摘要:
酒精性肝病是世界范围内引起慢性肝病的主要原因之一,疾病谱包括:单纯脂肪肝、酒精性肝炎和肝硬化等。 严重的酒精性肝病会引起肝脏炎症、肝细胞损伤、肝纤维化,可能须要联合治疗。现对已知的能够抑制炎症,减少肝细胞死 亡和促进肝脏修复的药物治疗靶点进行综述。
Abstract:
Alcoholic liver disease (ALD) is one of the main leading causes of chronic liver disease worldwide and its spectrum ranges from simple liver steatosis to alcoholic hepatitis and cirrhosis. Severe ALD can cause hepatic inflammation, hepatocellular damage, hepatic fibrosis and impaired liver regeneration, which likely requires combined therapies. In this paper, some identified therapeutic targets that inhibit inflammation, ameliorate hepatocyte death, and promote liver repair in ALD are reviewed.

参考文献/References

[1] Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets[J]. Gastroenterology, 2011, 141(5):1572– 1585.
[2] Wang HJ, Gao B, Zakhari S, et al. Inflammation in alcoholic liver disease[J]. Annu Rev Nutr, 2012, 32:343–368.
[3] Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis[J]. N Engl J Med, 2009, 360(26):2758–2769.
[4] Mathurin P, O'Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data[J]. Gut, 2011, 60(2):255–260.
[5] Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis[J]. N Engl J Med, 2011, 365(19):1781–1789.
[6] Rahimi E, Pan JJ. Prognostic models for alcoholic hepatitis[J]. Biomark Res, 2015, 3:20.
[7] Christensen E. Glucocorticosteroids in acute alcoholic hepatitis: the evidence of a beneficial effect is getting even weaker[J]. J Hepatol, 2010, 53(2):390–391.
[8] Lin F, Taylor NJ, Su H, et al. Alcohol dehydrogenase-specific T-cell responses are associated with alcohol consumption in patients with alcohol-related cirrhosis[J]. Hepatology, 2013, 58(1):314–324.
[9] Kwon HJ, Won YS, Park O, et al. Opposing effects of prednisolone treatment on T/NKT cell- and hepatotoxin-mediated hepatitis in mice[J]. Hepatology, 2014, 59(3):1094-1106.
[10] Dominguez M, Miquel R, Colmenero J, et al. Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis[J]. Gastroenterology, 2009, 136(5):1639–1650.
[11] Colmenero J, Bataller R, Sancho-Bru P, et al. Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity[J]. Gastroenterology, 2007, 132(2):687– 697.
[12] Chang B, Xu MJ, Zhou Z, et al. Short-or long-term high-fat diet feeding plus acute ethanol binge synergistically induce acute liver injury in mice: an important role for CXCL1[J]. Hepatology, 2015, 62(4):1070-1085.
[13] Bertola A, Park O, Gao B. Chronic plus binge ethanol feeding synergistically induces neutrophil infiltration and liver injury: a critical role for E-selectin[J]. Hepatology, 2013, 58(5):1814– 1823.
[14] Mandrekar P, Ambade A, Lim A, et al. An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury: regulation of proinflammatory cytokines and hepatic steatosis in mice[J]. Hepatology, 2011, 54(6):2185–2197.
[15] Magdaleno F, Ge X, Fey H, et al. Osteopontin deletion drives hematopoietic stem cell mobilization to the liver and increases hepatic iron contributing to alcoholic liver disease[J]. Hepatol Commun, 2017, 2(1):84-98.
[16] De Souza VCA, Pereira TA, Teixeira VW, et al. Bone marrowderived monocyte infusion improves hepatic fibrosis by decreasing osteopontin, TGF-β1, IL-13 and oxidative stress[J]. World J Gastroenterol, 2017, 23(28):5146-5157.
[17] Morales-Ibanez O, Dominguez M, Ki SH, et al. Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis[J]. Hepatology, 2013, 58(5):1742 –1756.
[18] Ge X, Leung TM, Arriazu E, et al. Osteopontin binding to lipopolysaccharide lowers tumor necrosis factor-alpha and prevents early alcohol-induced liver injury in mice[J]. Hepatology, 2014, 59(4):1600-1616.
[19] Seth D, Duly A, Kuo PC, et al. Osteopontin is an important mediator of alcoholic liver disease via hepatic stellate cell activation[J]. World J Gastroenterol, 2014, 20(36):13088-13104.
[20] Szabo G, Petrasek J. Gut-liver axis and sterile signals in the development of alcoholic liver disease[J]. Alcohol Alcohol, 2017, 52(4):414-424.
[21] Hartmann P, Chen P, Wang HJ, et al. Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice [J]. Hepatology, 2013, 58(1):108–119.
[22] Yan AW, Fouts DE, Brandl J, et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease[J]. Hepatology, 2011, 53(1):96–105.
[23] Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy[J]. N Engl J Med, 2010, 362(12):1071- 1081.
[24] McCullough RL, McMullen MR, Das D, et al. Differential contribution of complement receptor C5aR in myeloid and nonmyeloid cells in chronic ethanol-induced liver injury in mice[J]. Mol Immunol, 2016, 75:122-132.
[25] 陈星燃,卞勉励,张晨曦,等. 白介素1 家族在脂肪肝疾病 中的作用及机制研究进展[J]. 中国药理学通报,2017, 33(6):753-756.
[26] Jung Y, Brown KD, Witek RP, et al. Accumulation of hedgehogresponsive progenitors parallels alcoholic liver disease severity in mice and humans[J]. Gastroenterology, 2008, 134(5):1532– 1543.
[27] Sancho-Bru P, Altamirano J, Rodrigo-Torres D, et al. Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis[J]. Hepatology, 2012, 55(6):1931–1941.
[28] Gao B. Hepatoprotective and anti-inflammatory cytokines in alcoholic liver disease[J]. J Gastroenterol Hepatol, 2012, 27(Suppl 2):S89–S93.
[29] Kong X, Feng D, Wang H, et al. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice[J]. Hepatology, 2012, 56(3):1150–1159.
[30] Meng F, Wang K, Aoyama T, et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice[J]. Gastroenterology, 2012, 143(3):765– 776.
[31] Lu DH, Guo XY, Qin SY, et al. Interleukin-22 ameliorates liver fibrogenesis by attenuating hepatic stellate cell activation and downregulating the levels of inflammatory cytokines[J]. World J Gastroenterol, 2015, 21(5):1531-1545.
[32] Ki SH, Park O, Zheng M, et al. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronicbinge ethanol feeding: role of signal transducer and activator of transcription 3[J]. Hepatology, 2010, 52(4):1291–1300.
[33] Rubino SJ, Geddes K, Girardin SE. Innate IL-17 and IL-22 responses to enteric bacterial pathogens[J]. Trends Immunol, 2012, 33(3):112–118.
[34] Xu M, Feng D, Wang H, et al. IL-22 ameliorates renal ischemia -reperfusion injury by targeting proximal tubule epithelium[J]. J Am Soc Nephrol, 2014, 25(5):967-977.
[35] Park O, Wang H, Weng H, et al. In vivo consequences of liverspecific interleukin-22 expression in mice: implications for human liver disease progression[J]. Hepatology, 2011, 54(1):252–261.
[36] Choi Y, Abdelmegeed MA, Song BJ. Diet high in fructose promotes liver steatosis and hepatocyte apoptosis in C57BL/6J female mice: Role of disturbed lipid homeostasis and increased oxidative stress [J]. Food Chem Toxicol, 2017, 103:111-121.
[37] Roychowdhury S, McMullen MR, Pisano SG, et al. Absence of receptor interacting protein kinase 3 prevents ethanolinduced liver injury[J]. Hepatology, 2013, 57(5):1773–1783.

备注/Memo

备注/Memo:
[基金项目] 国家自然科学基金面上项目(81370530);国家 自然科学基金青年基金项目(81600467)
[通信作者]  邹正升,E-mail: zszou302@163.com; 薛兰, E-mail: xuelan1968@126.com
更新日期/Last Update: 2018-03-20